Table 3. Objective Response Rates to Atezolizumab Treatment and Duration of Response by Programmed Death Ligand 1 Immunohistochemical Status.
| Parameter | IC0/1 (n = 44) | IC2/3 (n = 50) | All Patients (N = 95)a |
|---|---|---|---|
| Objective response rate (95% CI)b | 11 (4 to 25) | 40 (26 to 55) | 26 (18 to 36) |
| Best overall response, No. (%) | |||
| Complete response | 1 (2) | 8 (16) | 9 (10) |
| Partial response | 4 (9) | 12 (24) | 16 (17) |
| Stable disease | 9 (21) | 9 (18) | 18 (19) |
| Progressive disease | 24 (55) | 17 (34) | 42 (44) |
| No assessmentc | 6 (14) | 4 (8) | 10 (11) |
| Duration of response, mo (range) | 27.6 (6.2 to >34.3) | 18.0 (2.8 to >41.0) | 22.1 (2.8 to >41.0) |
Abbreviation: IC, tumor-infiltrating immune cells.
a
Includes 1 patient with unknown programmed death ligand 1 IC immunohistochemical status.
b
Confirmed Response Evaluation Criteria in Solid Tumors version 1.1 objective responses assessed by investigator.
c
Refers to missing or unevaluable response status.